BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Expectations Audits

Viatris: The Stock That Trades Like a Dying Business While the Filings Show a Turning Corner

Moe Alsumidaie by Moe Alsumidaie
November 9, 2026
in Expectations Audits
0
81
SHARES
1.3k
VIEWS
Share on XShare on LinkedInShare on Facebook

Six years of falling revenue sit in Viatris’s history. The stock, meanwhile, has nearly doubled in the past year. Those two facts should not coexist without a very good explanation, and finding that explanation is exactly what this audit is for.

Viatris was born in November 2020 from a shotgun wedding between Mylan’s generic-drug empire and Pfizer’s Upjohn division, the home of off-patent blockbusters like Lipitor and Viagra. The logic was scale: combine Mylan’s manufacturing reach with Upjohn’s established brands and squeeze out costs. What followed instead was a long unwinding. The company sold its biosimilars unit, its over-the-counter brands, and its women’s health business, shedding billions in revenue to pay down the debt the merger created. By the time the 10-K for fiscal year 2025 landed, annual revenue had slid from its post-merger peak to $14.3 billion, a contraction that lasted every single year since 2021.

Now the question is whether the slide is ending or whether the stock has simply run ahead of a story that hasn’t changed yet.

First, the shape of it

The filings show a business that is shrinking more slowly, generating substantial cash, and actively raising its own financial targets. The stock is priced at a multiple that assumes almost no earnings power at all; whether that discount reflects rational skepticism about the pipeline or an overshoot depends on which revenue assumption one applies to 2027 and beyond. The open question is this: can a handful of specialty launches and one pending acquisition replace the revenue that patent expirations keep taking away?

BullScope TerminalWant the full evidence sheet behind pieces like this?The terminal runs the complete workup: Viatris and 500+ other names, on the same official data.See the evidence engine →

What the revenue line is actually doing

Revenue has fallen every year since 2021, but the rate of decline has been decelerating. The 2025 annual filing shows the drop slowing to about 3%, compared to roughly twice that rate the year before. And the 10-Q for the quarter ended September 30, 2026 shows $3.75 billion in quarterly revenue, putting the company on track for its first year of flat-to-positive operational growth since the merger. Management, after the November 5 earnings call, raised full-year 2026 revenue guidance to a range implying roughly two percent operational growth over 2025.

That is a small number, but the direction matters more than the magnitude right now. A business that was losing ground every year and is now holding ground is a different animal from one still in freefall. That inflection is the first data point the filed trend presents for weighing against the current price.

The cash the income statement hides

Reported earnings per share have been erratic, swinging between small gains and losses depending on restructuring charges and deal costs that run through the income statement. The cash flow picture is cleaner and considerably more flattering. The September 2026 10-Q shows free cash flow of $814 million for the third quarter alone, and management guided for full-year operating cash flow of roughly $2 billion to $2.1 billion.

To put that in household terms: imagine a family whose tax return looks terrible because of one-time moving costs, but whose actual take-home pay covers the mortgage twice over. The reported loss is real, but it is not the whole story of what the business generates. Adjusted EPS guidance for the full year now stands at $2.56 to $2.63, according to the updated guidance released November 5, which would represent about 8% operational growth versus 2025.

The debt that used to be the whole story

When Viatris formed, it inherited a debt load that dwarfed its annual earnings, and for years that was the dominant risk. The September 2026 10-Q shows long-term debt at $11.6 billion, meaningfully lower than at the end of 2025. Interest expense for the quarter fell compared to the same period a year earlier. The company is paying off roughly a billion dollars of debt per year, which matters because every dollar of interest that disappears is a dollar that can flow to shareholders or fund new products instead.

BullScope TerminalYou just read Viatris’ filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →

Liquidity looks solid: cash on hand as of September 30 was comfortable, with covenants confirmed in compliance. The pending acquisition of Pacira BioSciences, agreed in October 2026 for about $1.65 billion in equity value, will add to that debt load temporarily, but management describes it as immediately accretive to 2027 earnings. The debt story has shifted from existential to manageable, though it remains the largest single risk if revenue growth stalls again.

What the patent clock is taking away

The most concrete threat in the filings is not abstract competitive pressure. It is a calendar. LYRICA CR, a pain medication generating several billion dollars annually, saw its last listed patent expire in late 2026, opening it to generic competition. Revatio lost exclusivity earlier that same year. These are not surprises, but they are large, and new products have to run fast just to stay in place.

Viatris is running. The FDA approved the low-dose estrogen patch Gwyn Lo in July 2026, with a U.S. launch in October. The FDA accepted a new drug application for fast-acting meloxicam, a non-opioid pain treatment, in May 2026, with a decision expected by year-end and a potential launch in early 2027. Oppenheimer, in a September 2026 initiation note, argued the market is treating Viatris as a pure declining-generics story while missing the ophthalmology franchise, China growth, and the new-product pipeline, a view that illustrates the range of analytical frameworks applied to the same filings; that assessment reflects Oppenheimer’s own methodology and is cited here as one data point in the analytical landscape, not as a BullScope view. Management expects new product revenues of roughly $450 million for full-year 2026. That is real money, but it is not yet enough to fully offset what LYRICA CR alone could lose.

What the math says the mood is ignoring

Here is where the pessimism audit gets interesting. “The math” is what the filed fundamentals justify; “the mood” is what the market is currently paying, and those two readings are in unusual tension right now.

Based on trailing price-to-sales data from our published valuation methodology as of November 7, 2026, the stock is trading above its decade median on that measure, which on its face reads as expensive. But the adjusted EPS guidance for 2026 sits against a share price of $19.91, implying a forward multiple of about 7.7 times earnings. That is not the multiple of a business the market believes in. It is closer to the multiple of a business the market expects to keep shrinking. If earnings land at the guided range of $2.56–$2.63 and the forward multiple were to revert toward the company’s own historical median of approximately 11x (per our published methodology), the arithmetic would place the price in a range of roughly $28 to $29, a scenario that depends entirely on pipeline execution and continued debt reduction, neither of which is assured. We publish conditional scenario ranges in our published methodology, and the honest answer here is that the range is wide: the upside scenario requires the new pipeline to land and the debt to keep falling; the downside requires LYRICA CR erosion to accelerate faster than new products can fill the gap.

BullScope TerminalViatris was the article. The engine is the product.Same yardsticks, any ticker: filed financials in, math-vs-mood out. Nothing here is advice; it is the evidence, organized.Run another company →

GuruFocus, as of November 7, 2026, flagged Viatris as significantly overvalued based on its proprietary GF Value, a reminder that not every framework reads the same story from the same filings. That disagreement is itself informative: the valuation answer depends almost entirely on which revenue assumption one uses for 2027 and beyond.

Reading the numbers

  • $3.75 billion in Q3 2026 revenue (10-Q, September 30, 2026): what it is: one quarter’s total sales. What it means here: annualizes to roughly $15 billion, consistent with the guided full-year range and the first year of operational growth since 2021. Everyday example: a business that had been losing one customer a year just held its customer count flat for the first time.
  • 58% adjusted gross margin (same filing): what it is: of every dollar of sales, 58 cents remained after direct production costs. What it means here: generic-drug businesses typically run thinner; this margin reflects the shift toward branded and specialty products. Everyday example: a bakery that used to sell plain loaves at thin margins is now selling specialty sourdough at nearly twice the markup per loaf.
  • $11.6 billion in long-term debt (10-Q, September 30, 2026): what it is: the total borrowed money owed beyond the next twelve months. What it means here: at roughly $112 million in quarterly interest, the company is spending about what it earns in a week of sales just to service borrowing. Everyday example: a household earning $80,000 a year carrying a $60,000 balance, with payments falling every year as the balance shrinks.
  • $2.56 to $2.63 adjusted EPS guidance for 2026 (guidance, November 5, 2026): what it is: the company’s own estimate of earnings per share for the full year, adjusted to exclude one-time costs. What it means here: at a share price of $19.91, the implied forward multiple is approximately 7.7 times guided earnings, a ratio more typical of businesses the market expects to keep contracting than of businesses priced for growth. Analytical analogy: a commercial property appraised at a 13% cap rate, a level that usually signals the market is pricing in meaningful occupancy risk.

For the standing yardsticks on Viatris: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Viatris.

Sources

  • Viatris 10-Q, quarter ended September 30, 2026 (SEC EDGAR)
  • Viatris 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
  • 247Wall St: Viatris Q3 2026 earnings summary
  • Motley Fool: Viatris Q3 2026 earnings call transcript, November 5, 2026
  • Investing.com: Viatris raises guidance, November 5, 2026
  • Finimize: Oppenheimer initiates Viatris, September 2026
  • Barchart: analyst rating distribution and price targets, November 2026
BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read Viatris’ filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Organon at $13.90: The Price That Assumes a Soft Landing the Filings Don’t Quite Confirm

by Moe Alsumidaie
November 16, 2026
0

Sun Pharmaceutical Industries is paying $14.00 a share to buy Organon. The stock trades at $13.90. Those two numbers, sitting ten cents apart, should end the conversation. They...

Read moreDetails

Gilead at Its All-Time High: Three Claims the Filings Put to the Test

by Moe Alsumidaie
November 2, 2026
0

Gilead spent most of the 2010s as the company that cured hepatitis C, then watched that revenue stream shrink as it ran out of patients to cure. The...

Read moreDetails

Eli Lilly: The Margin the Price Believes In

by Moe Alsumidaie
October 26, 2026
0

Four years ago, Eli Lilly was a solid, slow-moving pharmaceutical company with a net margin hovering around 20% and a stock that rewarded patience rather than excitement. Then...

Read moreDetails

Visa’s Price Assumes the Party Ends. The Filings Say It Hasn’t.

by Moe Alsumidaie
October 23, 2026
0

Payments volume crossed $4 trillion in a single quarter for the first time in Visa's history this past July. Four weeks later, the stock was sitting at an...

Read moreDetails

Vertex Pharmaceuticals: Three Things the Street Is Saying, and What the Filings Actually Show

by Moe Alsumidaie
October 21, 2026
0

Vertex spent most of the last decade as a one-disease company that happened to be extraordinarily good at that disease. Cystic fibrosis is rare, the science is brutal,...

Read moreDetails
Next Post

Moderna swings to profit as revenue growth accelerates to 29%, raises full-year outlook to 15-25%

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

The Grocery Giant’s Quiet Reinvention: What Walmart’s Filed Numbers Say About the American Consumer

August 3, 2026

Lowe’s: The Stock Is Down a Quarter, the Business Just Grew 10%. The Gap Is the Story.

August 18, 2026

Gilead’s Books Say One Thing. The Price Tag Says Another. Here’s What the Filings Actually Show.

October 12, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.